PRISMAP final event

The final PRISMAP public event will take place on 18–19 November 2025 in Warsaw and online.

On this occasion, we will report on the highlights of PRISMAP user projects and our own research activities. We will also discuss the lessons learnt from this research infrastructure project, the conclusions and our way forward.

Moreover, there will be a poster session for which all participants are kindly invited to bring a poster.

Agenda

Day 1

18 November 2025

Meeting link for day 1

13.00	Registration
13.30	PRISMAP in a nutshell	Thierry Stora, CERN
14.00	Welcome to the Heavy Ion Laboratory (HIL)	Dr Jaroslaw Choiński, Deputy director of HIL
PRISMAP final results Chair: Renata Mikolajczak
14.30	Strategic engagement with emerging infrastructures	Lucia-Ana Popescu, SCK CEN
14.50	Development and optimisation of targets, ion sources, and enrichment techniques for medical radionuclide production	Mattia Manzolaro, INFN
15.10	Poster session – Networking and refreshments
16.00	Results and lessons learned from 4 years of transnational transport of novel radionuclides	Mikael Jensen, DTU
16.20	Medically relevant radiolanthanides: Exploring today's breakthroughs and tomorrow's possibilities	Zeynep Talip, PSI
PRISMAP services Chair: Ferid Haddad
16.40	PRISMAP services for radionuclide production and their biomedical application	Ulli Köster, ILL
17.00	PRISMAP services seen from the perspective of the user selection panel	Conny Hoehr, TRIUMF
17.20	New in-vivo models and new radionuclides for efficient evaluation of targeted radionuclide therapy: User feedback towards clinical translation	Clement Morgat, Université Bordeaux
17.40	Wrap-up of day 1	Thierry Stora, CERN
18.00	End of day one

Day 2

19 Novenber 2025

Meeting link for day 2

8.30	Reception
Regulatory Requirements Chairs: Sean Collins, Clemens Decristoforo
9.00	Experience with novel radionuclides in radiopharmacy	Serge Lyashchenko, MSK Cancer Center
9.20	A bumpy road to standardize and harmonize the regulatory requirements for radiopharmaceutical production involving novel radionuclides	Clemens Decristoforo, Medical University Innsbruck
9.40	Translational data generation	Seán Collins, NPL
10.00	Open discussion	Clemens Decristoforo, Medical University Innsbruck
10.30	Short break with poster session
The European perspective Chair: Thierry Stora
10.45	Keynote: Research infrastructures and the need to provide access to novel radionuclides and their biomedical application	Patricia Postigo McLaughlin, DG RTDi
Industrial Collaboration Chairs: Thierry Stora, Renata Mikolajczak
11.00	10 years of experience in radiopharmacy of the Synektik S.A. Research and Development Centre	Łukasz Steczek, Synektik Pharma Sp. z o.o.
11.30	New Voxel Innovation Campus – challenges and perspectives for Polish radiopharmaceutical community	Marek Pilch-Kowalczyk, Technology Advisor, Voxel SA
12.00	NCBJ Radioisotope Centre POLATOM in the logistics of radioactive goods	Tomasz Chwaliński, Head of Air Transport Section, NCBJ POLATOM
12.30	Polysaccharide nanoparticles as drug and isotope carrier in cancer therapy	Tomasz Ciach, Warsaw University of Technology
13.00	Lunch
Results from the user projects enabled by PRISMAP Chair: Thomas Cocolios
14.30	General overview of theranostics impact in oncology	Jolanta Kunikowska, Warsaw Medical University
15.00	Translational investigations of new PSMA-targetting radiobioconjugates based on theranostic Pb-203 and Pb-212 (tentative)	Marc Pretze, Constantin Mamat, Carmen Waengler, Universität Dresden, Universitätsmedizin Mannheim
15.30	Short break with poster session
16.00	The first studies and perspectives for positronium imaging using 52Mn	Pawel Moskal, Jagiellonian University in Krakow, Poland
16.30	Treatment Efficacy of 161Tb-Labeled GRPR Ligands in Comparison with their 177Lu-Labeled Analogs	Thomas Guenther, Stanford University, USA
17.00	Wrap-up of day 2 and closure of the public event	Thierry Stora, CERN
17.30	End of day 2